Introduction {#S0001}
============

Colorectal cancer (CRC) is one of the most common malignancies worldwide and the third leading cause of cancer-related death in humans \[[@CIT0001], [@CIT0002]\]. Nearly eight million new colorectal cancer cases are diagnosed each year worldwide. Despite great improvement in the treatment of CRC, the prognosis of patients remains poor. Current clinical and pathological parameters are not sufficient to precisely predict clinical outcome of CRC. Therefore, it is urgent to explore novel molecular biomarkers to discriminate patients with different molecular pathological profiles, thus helping the elucidation of CRC carcinogenesis and the individualized treatment decision \[[@CIT0003]\].

Mitochondria play a pivotal role in multiple physiological processes including energy production, catabolic and anabolic metabolism, generation of reactive oxygen species (ROS) and apoptosis. Mitochondrial dysfunction has long been implicated in the development of various malignancies, including CRC \[[@CIT0004]\]. Somatic mitochondrial DNA (mtDNA) mutations, which are believed to be the consequence of ROS insult, have been observed in many types of cancers \[[@CIT0005]\]. However, little is known about how mitochondrial alterations are involved in the process of carcinogenesis. Warburg first suggested that mitochondrial dysfunction-triggered aerobic glycolysis is the crucial metabolic pattern in cancer cells \[[@CIT0006]\]. However, recent research has demonstrated that functional mitochondria are also important to support rapid growth of most tumor cells \[[@CIT0007]\].

Previous analyses of mitochondrial dysfunction in cancer have typically focused on the alterations of mtDNA, including its content and mutations \[[@CIT0005], [@CIT0008], [@CIT0009]\]. However, studies in the aging colon have demonstrated that immunostaining of cytochrome c oxidase (COX) is also a good surrogate indicator of mitochondrial function \[[@CIT0010]\]. COX consists of 3 mtDNA-encoded and 10 genomic DNA-encoded subunits, forming complex IV of the electron transport chain \[[@CIT0011]\]. In the aging colon, COX loss involves whole crypts, presumably as a consequence of mtDNA mutations that occur in the stem cells and then propagate along the crypt \[[@CIT0010], [@CIT0012]\]. In addition, COX loss has been observed in colon epithelia insulted by ulcerative colitis, a premalignant lesion of colon cancer \[[@CIT0013]\]. However, CRC cells show higher COX expression than either ulcerative or normal colon epithelia, indicating a complex role of COX expression alterations in the transformation of colon epithelia.

In the 13 subunits of COX, subunit IV (COX IV) plays a critical role in the assembly of COX. Although mtDNA exhibits a large copy number and high transcriptional activity \[[@CIT0014]\], lower COX activity has been reported in a variety of mammalian cell types \[[@CIT0015]\], implying the limiting role of COX IV in COX assembly. In previous studies, only mtDNA-encoded subunits I (COX I), II (COX II) and III (COX III) have been investigated in CRC \[[@CIT0013]\]. However, expression level of the three subunits is not sufficient to reflect the activity of COX as an entire enzyme complex. Therefore, it is more useful to examine the expression of COX IV in exploring the biological functions of COX in CRC.

Nevertheless, to date, little is known about the biological functions of COX IV in CRC. We thus performed real-time PCR, Western blot and immunohistochemistry (IHC) to investigate the expression of COX IV in CRC tissues \[[@CIT0016]\]. In addition, we analyzed its association with clinicopathological parameters and prognostic value in CRC.

Material and methods {#S0002}
====================

Study population {#S20003}
----------------

A total of 339 CRC patients who underwent curative surgery were consecutively recruited during the period from August 2008 to August 2012 in an ongoing epidemiological study at the Department of General Surgery, Xijing and Tangdu Hospitals, Fourth Military Medical University, Xi\'an, China. Eligibility criteria of patient enrollment were as follows: a) colorectal adenocarcinoma diagnosed by histopathological examination; b) surgical treatment including colectomy and lymphadenectomy (limited or extended); c) availability of complete follow-up data; d) no preoperative treatment, such as chemotherapy and radiotherapy; e) no history of familial malignancy or other synchronous malignancy; and f) no death within 1 month after the operation. The histopathological type was determined using the criteria of the World Health Organization (WHO) classification. All the colorectal adenocarcinomas were graded based on their glandular differentiation degree, with grade 1 for well-differentiated adenocarcinomas (more than 95% of tumor composed of glands), including tubular adenocarcinomas; grade 2 for moderately differentiated adenocarcinomas (50--95% of tumor composed of glands), and grade 3 for poorly differentiated carcinomas (49% or less of tumor composed of glands). All patients were staged according to the seventh-edition Tumor-Node-Metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC). Postoperative follow-up, including physical and laboratory examinations, was performed at the outpatient department every 3 months for the first 2 years, every 6 months for the third to fifth years, and annually thereafter until at least 5 years after the operation or until the patient died, whichever came first. The last follow-up date was August, 2013. Informed consent was obtained from each patient.

This study was approved by the Ethical Committee of the Fourth Military Medical University and performed in accordance with the ethical standards of the Helsinki Declaration.

Tissue samples {#S20004}
--------------

For real-time quantitative polymerase chain reaction (PCR) analysis, a total of 23 paired cancerous tissues and matched adjacent pericancerous tissue located at least 2 cm away from the cancer were randomly selected. The 23 patients included 10 men and 13 women, with a median age of 73 years (range: 44--81 years).

For immunohistochemical staining, formalin-fixed, paraffin-embedded primary colorectal adenocarcinoma samples were collected from the 339 patients mentioned above and stored at room temperature. HE slides from these patients were viewed under a light microscope by pathologists and 3-µm-thick tissue sections were cut from corresponding blocks containing representative tumor regions.

For Western blot analysis, there pairs of representative tissues were selected based on the IHC results (IHC-positive cancer tissues and IHC-negative pericancerous tissues).

Quantitative real-time PCR {#S20005}
--------------------------

Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer\'s protocol. Then, two micrograms of RNA was reverse transcribed into first-strand cDNA by M-MLV Reverse Transcriptase (Promega) according to the manufacturer\'s instructions. COX IV and 18s rRNA were amplified by quantitative real-time PCR using the following primers: COX IV forward: 5'-GAGTTGTATCGCATTAAGTTCAAGGAGAG-3', reverse: 5'-ACACATAGTGCTTCTGCCACATGATAA-3'; 18s rRNA forward: 5'-GACACGGACAGGATTGACAGATTGAT-3', reverse: 5'-ATGCCAGAGTCTCGTTCGTTATCG-3'. Gene-specific amplification was performed by the Bio-Rad CFX96 real-time PCR system. The relative expression of COX IV mRNA was normalized to the expression of 18s rRNA using 2^--ΔΔCt^ method as previous described \[[@CIT0017]\].

Western blot {#S20006}
------------

Homogenized tissues were lysed in RIPA lysis buffer, and protein samples (20 µg) were separated by electrophoresis in a 12% denaturing polyacrylamide gel. Blots were incubated with the primary antibodies at 4°C overnight, then incubated with secondary HRP-conjugated anti-rabbit antibody for 60 min. The bands were detected with an enhanced chemiluminescence reagent (Millipore). Band density was measured with Quantity One image analysis software and was standardized to that of β-actin.

Immunohistochemical staining {#S20007}
----------------------------

Sections were incubated with antibody of COX IV (1: 200, Abcam) or rabbit anti-human PCNA (1: 2000, Cell Signaling Technology). The visualization signal was developed with the Invitrogen Histostain Plus kit. The intensity and extent of COX IV immunostaining were evaluated for all samples under double-blinded conditions. In brief, the percentage of positive staining was scored as 0 (0--9%), 1 (10--25%), 2 (26--50%), 3 (51--75%) or 4 (76--100%), and the intensity as 0 (no staining), 1 (weak staining), 2 (moderate staining) or 3 (dark staining). The total score was calculated as the product of intensity and extent, ranging from 0 to 12.

Statistical analysis {#S20008}
--------------------

All statistical analyses were performed using the SPSS Statistics 19.0 software (IBM). Differences in mRNA and protein expression between cancerous and pericancerous tissues were evaluated with the Wilcoxon test. The χ^2^ test was used to analyze the relationships between COX IV expression and various clinicopathological parameters. The Mann-Whitney *U* test was used to compare the PCNA IHC score between patients with high and low COX IV expression. Kaplan-Meier survival function was calculated and compared with the log-rank test. The Cox proportional hazard regression model was used for univariate and multivariate analyses to explore the effects of the clinicopathological variables and COX IV expression on survival. All statistical tests were two-tailed and *p* \< 0.05 was considered to be significant.

Results {#S0009}
=======

COX IV expression was significantly increased in CRC cells at mRNA and protein levels {#S20010}
-------------------------------------------------------------------------------------

We first measured COX IV mRNA levels in 23 paired cancerous and adjacent pericancerous tissues using quantitative real-time PCR. As shown in [Figure 1 A](#F0001){ref-type="fig"}, COX IV mRNA expression level was higher in colorectal cancer tissues than that in the corresponding pericancerous tissues (*p* = 0.05), and 65.2% of the subjects (15/23) displayed higher COX IV mRNA expression in cancer tissues, compared with paired tissues.

![mRNA and protein expression of COX IV in CRC tissues. COX IV expression was significantly upregulated at both mRNA (**A**) and protein (**C**) levels in CRC tissues. Band intensity was quantified using Quantity One image analysis software (**D**). mRNA expression level of COX IV in male patients is lower than that in females (**B**)](AMS-12-26840-g001){#F0001}

To validate the qPCR findings, we performed immunohistochemical analyses of 339 colorectal cancer tissue blocks. As shown in [Figure 2](#F0002){ref-type="fig"}, COX IV expression was higher in cancer tissues than in adjacent noncancerous tissues (*p* \< 0.001). We then determined COX IV protein levels in three pairs of representative samples by Western blot. Consistent with the quantitative real-time PCR and IHC results, Western blot analysis confirmed the significantly increased COX IV expression in CRC tissues when compared to their respective adjacent normal tissues ([Figures 1 C](#F0001){ref-type="fig"}, [D](#F0001){ref-type="fig"}).

![COX IV and PCNA expression in CRC tissues examined by immunohistochemistry. Representative intratumoral (**A, D, G**) and peritumoral (**B, E, H**) immunohistochemical staining of COX IV and representative intratumoral immunohistochemical staining of PCNA (**C, F, I**) are shown. Mann-Whitney test showed elevated COX IV expression in CRC tissues compared to pericancer tissues (J). In addition, there was no significant difference in PCNA expression between CRC samples with high or low COX IV expression (**K**)](AMS-12-26840-g002){#F0002}

Up-regulated COX IV expression was located in cytoplasm and not associated with cell proliferation {#S20011}
--------------------------------------------------------------------------------------------------

COX IV protein was mainly expressed in cytoplasm of both cancer cells and pericancer cells. Considering the elevated expression level of COX IV in CRC, we hypothesized that elevated COX IV expression is involved in the carcinogenesis of CRC and thus explored the potential association between COX IV and PCNA expression. However, we failed to observe a significant association between expression of the two molecules ([Figure 2 K](#F0002){ref-type="fig"}), implying the potential possibility that COX IV expression was not associated with CRC cell proliferation.

COX IV expression was not associated with clinicopathological characteristics of CRC except gender {#S20012}
--------------------------------------------------------------------------------------------------

There were 150 (44.2%) female and 189 (55.8%) male patients, with a median age of 63 years (range: 25--90 years). The median follow-up for the entire cohort was 57 months (range: 3--81 months). Among the 339 patients, 159 (46.9%) were diagnosed with colon cancer and 215 (53.1%) with stage I--II disease. After dividing patients into high or low expression subgroups with the median IHC score of COX IV in cancer tissues, we further analyzed the association between COX IV expression level and clinical characteristics of CRC patients. As shown in [Table I](#T0001){ref-type="table"}, there was no significant association between COX IV expression and most patients' clinical characteristics. However, female patients showed a higher expression level than did males (*p* = 0.017), and this result is also confirmed by qPCR (*p* = 0.025) ([Figure 1 B](#F0001){ref-type="fig"}).

###### 

Associations of COX IV expression with characteristics of CRC patients

  Variables                  No. of cases   COX IV expression   *P* (χ^2^ test)   
  -------------------------- -------------- ------------------- ----------------- -------
  Total                      339            167                 172               
  Age \[years\]:                                                                  0.780
   \< 63                     174            87                  87                
   ≥ 63                      165            80                  85                
  Gender:                                                                         0.017
   Female                    150            63                  87                
   Male                      189            104                 85                
  Tumor locus:                                                                    0.424
   Rectum                    180            85                  95                
   Colon                     159            82                  77                
  Tumor number:                                                                   0.976
   Single                    335            165                 170               
   Multiple                  4              2                   2                 
  Maximal diameter \[cm\]:                                                        0.260
   \< 5                      160            84                  76                
   ≥ 5                       179            83                  96                
  CEA \[µg/l\]:                                                                   0.477
   \< 10                     252            127                 125               
   ≥ 10                      87             40                  47                
  Grade:                                                                          0.464
   I/II                      298            149                 149               
   III                       41             18                  23                
  TNM stage:                                                                      0.638
   I--II                     215            108                 107               
   III--IV                   124            59                  65                
  Adjuvant therapy:                                                               0.982
   No                        57             28                  29                
   Yes                       282            139                 143               
  Death:                                                                          0.134
   No                        252            104                 148               
   Yes                       87             28                  59                
  Relapse:                                                                        0.216
   No                        236            97                  139               
   Yes                       103            35                  68                

CEA -- carcinoembryonic antigen, COX IV -- cytochrome c oxidase subunit IV.

COX IV expression was not associated with CRC patients' prognosis {#S20013}
-----------------------------------------------------------------

We also explored the prognostic value of COX IV expression in CRC. As shown in [Figures 3 A](#F0003){ref-type="fig"}, [B](#F0003){ref-type="fig"}, there was no significant difference in either overall survival (OS) or relapse-free survival (RFS) between patients with low and high COX IV expression. Univariate Cox regression analyses revealed that OS was significantly decreased with higher TNM stage (*p* \< 0.001), higher differentiation grade (*p* = 0.010), and high serum carcinoembryonic antigen (CEA) concentration (*p* = 0.036), while RFS significantly decreased with higher TNM stage (*p* \< 0.001), higher differentiation grade (*p* = 0.001), and CEA (*p* = 0.003) ([Table II](#T0002){ref-type="table"}). Furthermore, multivariate Cox regression analyses confirmed TNM stage (*p* \< 0.001) and differentiation grade (*p* = 0.009) as significant independent predictors of OS of CRC patients, whereas TNM stage (*p* \< 0.001) and differentiation grade (*p* = 0.006) were significant independent prognostic factors for RFS ([Table II](#T0002){ref-type="table"}). Considering different expression level of COX IV in male and female patients, we performed survival analysis stratified by gender. As shown in [Figures 3 C](#F0003){ref-type="fig"}--[F](#F0003){ref-type="fig"}, no prognostic significance of COX IV was observed in either gender.

![Kaplan-Meier survival curves of patients with different COX IV expression levels. There was no significant difference in the OS (**A**) or RFS (**B**) of CRC patients with different COX IV levels. Furthermore, stratified analysis by gender showed that there was no significant difference in the OS (**C** for males and **E** for females) or RFS (**D** for males and **F** for females) of CRC patients with different COX IV levels in either gender](AMS-12-26840-g003){#F0003}

###### 

Univariate and multivariate Cox regression analysis of prognostic factors in colorectal cancer patients

  Variables          OS                     RFS                                                                                                   
  ------------------ ---------------------- ---------- ---------------------- ---------- ---------------------- ---------- ---------------------- ----------
  Age                0.851 (0.557--1.298)   0.453      0.770 (0.498--1.191)   0.24       0.740 (0.501--1.095)   0.132      0.756 (0.490--1.166)   0.206
  Gender             0.865 (0.568--1.317)   0.499      0.966 (0.629--1.482)   0.872      1.068 (0.723--1.579)   0.741      0.966 (0.631--1.481)   0.875
  Locus              1.029 (0.676--1.568)   0.892      0.963 (0.606--1.528)   0.872      0.885 (0.600--1.306)   0.539      0.966 (0.608--1.533)   0.883
  Maximal diameter   1.176 (0.767--1.803)   0.458      1.018 (0.637--1.627)   0.94       1.078 (0.731--1.592)   0.704      1.090 (0.682--1.743)   0.718
  Tumor number       1.072 (0.149--7.732)   0.945      0.631 (0.083--4.779)   0.655      0.806 (0.112--5.814)   0.83       0.600 (0.079--4.544)   0.621
  CEA                1.606 (1.032--2.499)   0.036      1.391 (0.876--2.210)   0.162      1.833 (1.228--2.735)   0.003      1.429 (0.900--2.270)   0.131
  Grade              1.690 (1.135--2.515)   0.01       2.011 (1.189--3.400)   0.009      2.330 (1.439--3.773)   0.001      2.099 (1.243--3.544)   0.006
  TNM stage          2.344 (1.538--3.574)   \< 0.001   3.227 (1.919--5.426)   \< 0.001   2.376 (1.613--3.501)   \< 0.001   3.310 (1.984--5.521)   \< 0.001
  Adjuvant therapy   0.626 (0.383--1.024)   0.062      0.329 (0.180--0.602)   \< 0.001   0.656 (0.412--1.043)   0.074      0.338 (0.194--0.589)   \< 0.001
  COX IV             1.056 (0.690--1.617)   0.8        1.026 (0.665--1.582)   0.909      0.922 (0.625--1.360)   0.683      1.075 (0.698--1.654)   0.743

HR -- hazard ratio, CI -- confidence interval, OS -- overall survival, RFS -- relapse-free survival.

Discussion {#S0014}
==========

In this study, we examined the expression of COX IV and its association with clinical characteristics in CRC patients. We found that COX IV expression was elevated in CRC tissues when compared with adjacent noncancerous tissues. In addition, female patients showed higher COX IV expression than male patients. We also explored the prognostic value of COX IV in CRC patients. However, we observed no significant association between COX IV expression and clinical outcome of CRC patients.

COX is an important mitochondrial multi-protein complex with two main substrates -- oxygen and cytochrome c \[[@CIT0018]\]. The physiological role of COX as an electron carrier is well known; however, its biological functions in the development of cancer have not been fully demonstrated. The alterations of COX in the pathogenesis of malignancies have been investigated in several studies. As the result of ROS injury accumulation, mutations of mtDNA-encoded subunits of COX (COX I to III) are well understood in a number of tumors, including CRC \[[@CIT0019], [@CIT0020]\], prostate cancer \[[@CIT0021], [@CIT0022]\], hepatocellular carcinoma \[[@CIT0023]\] and myelodysplastic syndrome \[[@CIT0024]\]. In addition to mtDNA-encoded COX subunits, genomic DNA-encoded subunits, especially COX V, are also studied in several tumor types. Increased expression of COX Va has been observed in lung cancer \[[@CIT0025]\] and renal cell carcinoma \[[@CIT0026]\]. Furthermore, the expression of COX I and III is repressed in premalignant colon epithelia but increased in CRC tissues \[[@CIT0013]\]. In line with these findings, we observed the elevated COX IV expression in CRC tissues. These data collectively suggest that alterations of COX expression may play an important role in the pathogenesis of CRC.

The cause of elevated COX IV expression in CRC remains unclear. Previous studies have demonstrated that the expression of COX II and IV is gradually depressed during the differentiation of murine erythroleukemia cells \[[@CIT0027]\]. Therefore, it is not surprising that COX IV expression was upregulated in the development of CRC, a reverse procedure of differentiation. Indeed, Wu *et al*. demonstrated that autocrine gastrin increases COX Vb expression in colon cancer HCT-116 cells \[[@CIT0028]\]. In lung adenocarcinoma cells, it has been reported that induction of activated H-Ras^V12^ enhances the expression of COX Vb \[[@CIT0029]\]. In our study, we also found that female CRC patients showed higher COX IV expression than male patients. The higher prevalence of COX IV-overexpressed tumors in women, together with the lack of prognostic impact of COX IV expression in female CRC, indicates the possibility of a link between hormonal factors and COX IV expression status in CRC, and the underlying mechanisms of this impact need to be further elucidated. Therefore, an influence of anthropometric and lifestyle factors is also plausible and should be pursued in future studies.

Although there are several studies focused on the biological functions of COX units in the development of tumors, the role of elevated expression of COX IV in CRC remains to be elucidated. Chen *et al*. reported that knockdown of COX Va expression substantially suppresses the migration and invasion of non-small cell lung cancer (NSCLC) cells through inhibition of metalloproteinases MMP-2 and MMP-9 \[[@CIT0025]\]. Moreover, elevated COX Va expression is associated with higher N stage and poorer prognosis of patients with lung adenocarcinoma. In glioblastoma multiform (GBM), increased COX Va activity has been associated with acquisition of temozolomide chemoresistance \[[@CIT0030]\], as well as shorter progression-free survival and OS of patients \[[@CIT0031]\]. Liang *et al*. also confirmed that COX Vb is involved in the metastatic potential of CRC cells \[[@CIT0032]\]. Despite the important role of COX expression alteration in the carcinogenesis of colon epithelia \[[@CIT0013]\], we observed no association of COX IV expression with proliferation and progression of CRC, as indicated by PCNA staining and TNM stage respectively. Furthermore, we failed to observe the prognostic value of COX IV expression. One explanation of these differences is that alterations of different COX subunits may contribute to different stages of CRC development. Proteomic studies have demonstrated that the ratio of nuclear encoded COX subunits to mtDNA-encoded COX subunits increases during the progression of carcinogenesis, suggesting the coordination of COX subunit alterations in the reprogramming of cancer metabolism \[[@CIT0033], [@CIT0034]\]. In addition, differences in study design, ethnic background, population sampling and experimental protocols may also account for the differences between our data and others. Therefore, the role of COX IV in the development of CRC needs to be further investigated in future studies.

In conclusion, our study for the first time demonstrated the elevation of COX IV expression levels in CRC tissues compared with adjacent nontumor tissues. In addition, the expression level of COX IV in female patients was higher than that in male patients. However, we did not find any association of COX IV expression with the progression of CRC or prognosis of patients. Our findings contribute to the current understanding of the COX subunit in the procedure of CRC development, which warrants further investigation in the alterations of the respiratory chain in CRC.
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